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Abstract
Trans-sialidase (TS), a virulence factor from Trypanosoma cruzi, is an enzyme playing key roles in the biology of this
protozoan parasite. Absent from the mammalian host, it constitutes a potential target for the development of novel
chemotherapeutic drugs, an urgent need to combat Chagas’ disease. TS is involved in host cell invasion and parasite
survival in the bloodstream. However, TS is also actively shed by the parasite to the bloodstream, inducing systemic effects
readily detected during the acute phase of the disease, in particular, hematological alterations and triggering of immune
cells apoptosis, until specific neutralizing antibodies are elicited. These antibodies constitute the only known submicromolar
inhibitor of TS’s catalytic activity. We now report the identification and detailed characterization of a neutralizing mouse
monoclonal antibody (mAb 13G9), recognizing T. cruzi TS with high specificity and subnanomolar affinity. This mAb displays
undetectable association with the T. cruzi superfamily of TS-like proteins or yet with the TS-related enzymes from
Trypanosoma brucei or Trypanosoma rangeli. In immunofluorescence assays, mAb 13G9 labeled 100% of the parasites from
the infective trypomastigote stage. This mAb also reduces parasite invasion of cultured cells and strongly inhibits parasite
surface sialylation. The crystal structure of the mAb 13G9 antigen-binding fragment in complex with the globular region of
T. cruzi TS was determined, revealing detailed molecular insights of the inhibition mechanism. Not occluding the enzyme’s
catalytic site, the antibody performs a subtle action by inhibiting the movement of an assisting tyrosine (Y119), whose
mobility is known to play a key role in the trans-glycosidase mechanism. As an example of enzymatic inhibition involving
non-catalytic residues that occupy sites distal from the substrate-binding pocket, this first near atomic characterization of a
high affinity inhibitory molecule for TS provides a rational framework for novel strategies in the design of chemotherapeutic
compounds.
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Introduction
Chagas’ disease, the American trypanosomiasis, is a chronic
disabling parasitic disease caused by the flagellate protozoon
Trypanosoma cruzi. With an estimated global burden of 100 million
people at risk, 8 million already infected, and approximately
40,000 new cases/year, Chagas’ disease represents a major health
and economic problem in Latin America [1]. The infection is
naturally transmitted by triatomine vectors (‘‘kissing bugs’’), from
the south of the USA to the southern region of South America,
although chagasic patients are in fact dispersed worldwide due to
migrations. Patients can also transmit the disease either by in utero
infection leading to the congenitally acquired disease or by
accidental transmission through contaminated blood. The acute
infection is characterized by patent parasite burden. During this
initial stage, T. cruzi induces several alterations in the infected
mammal including intense polyclonal activation of lymphocytes
[2], transient thymic aplasia [3,4] and other clinical hematological
findings [5,6]. The majority of the patients control the parasit-
emia, survive the acute phase, and enter into an indeterminate
form of the disease that may last for many years or even
indefinitely [1]. Up to 20 years after the infection, ,35% of
patients develop different pathologies, such as cardiomyopathy,
peripheral nervous system damage, and/or dysfunction of the
digestive tract [1].
Sialic acids have proven to be crucial during the parasite’s life
cycle and survival in the mammalian host [7–10]. However, T.
cruzi is unable to perform de novo synthesis of sialic acids [11]. This
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the host’s glycoconjugates, through a glycosyl-transfer reaction
mediated by trans-sialidase (TS), a modified sialidase expressed by
the parasite. In this way, the surface of the parasite becomes
rapidly sialylated, with mucins being the main sialyl acceptors, in a
process that allows the parasite to evade its destruction by serum
factors [9,10]. TS activity is also involved in host cell attachment
and invasion [7,8], as well as in parasite escape from the
parasitophorous vacuole into the cytoplasm, where the parasite
replicates [12].
In the trypomastigote stage, TS is a glycosylphosphatidylinosi-
tol-anchored non-integral membrane protein [13], actively
released to the extracellular milieu, leading to a systemic
distribution of the enzyme through the bloodstream. Its half-life
in blood is significantly extended due to the presence of a C-
terminal repetitive domain named SAPA [14]. TS activity is
detectable in the bloodstream of infected humans and mice, until
antibodies able to neutralize its catalytic activity are elicited [15].
The systemic distribution of TS is associated with several
pathologies observed during the early steps of infection including
depletion of thymocytes [16], absence of germinal centers in
secondary organs [17] and thrombocytopenia and erythropenia
[5,6], all alterations that can be prevented by the passive transfer
of TS-neutralizing antibodies [17,18]. In fact, administration of
the enzyme in mice before T. cruzi challenge, leads to more severe
evolution of the infection [19]. These finding are also consistent
with the fact that increased shedding of the enzyme correlates with
increased virulence of the corresponding parasite strains [20].
TS has thus been identified as a potential target for drug
discovery and design. Added to its key roles in host response
evasion, cell invasion and pathogenesis, TS is not present in the
mammalian host. The development of suitable drugs to treat/
prevent Chagas’ disease is urgently needed [21]. Only two
compounds, benznidazol and nifurtimox, are currently available
for treating both acute and chronic infections. These drugs are far
from being optimal: fairly toxic, they trigger serious side effects,
while also showing suboptimal efficacy in a high proportion of
patients. The emergence of resistant parasite strains adds a
concerning issue [22]. Several attempts to obtain suitable TS
inhibitors have been made, especially once its 3D structure
became available [23,24]. However, only low affinity molecules
have been obtained so far [25,26], some of them toxic in in vivo
assays [27], ultimately suggesting that further and more active
efforts must be pursued.
We have obtained a TS-neutralizing mouse monoclonal
antibody (mAb 13G9) that displays very high affinity and
specificity towards the T. cruzi enzyme. This mAb is able to
prevent immune system and hematological abnormalities, even
when assaying highly virulent parasites under lethal infection
conditions [5,17]. We now report an extensive functional
characterization of mAb 13G9, as well as the crystal structure of
the 13G9-TS binary complex. The molecular features of the
inhibitory mechanism are unveiled, providing novel insight for the
development of TS inhibitors, which might also be relevant for
related neuraminidases in other pathogens.
Results
Biochemical Characterization of the TS-neutralizing
Monoclonal Antibody
Mice were immunized with a TS recombinant protein
(D1443TS), identical to the wt except it includes a deletion of a
non-neutralizing epitope. D1443TS retains full enzymatic activity,
while avoiding the otherwise typical delay in eliciting TS-
neutralizing antibodies [28,29]. Hybridomas were screened by
TS-inhibition assay [30] and the 13G9 clone secreting a TS-
neutralizing mAb (IgG2ak) was obtained. The specificity of this
mAb was confirmed by the absence of reactivity against the closely
related sialidase from Trypanosoma rangeli and the TS from
Trypanosoma brucei (data not shown). As depicted in Figure 1A, this
mAb showed high affinity for the T. cruzi TS (KD ,7.2610
210 M)
as calculated from the kinetic constants determined by surface
plasmon resonance. In agreement, isothermal titration calorimetry
assays indicated an equilibrium dissociation constant lower than
10
29 M (raw data not shown).
The mAb was purified by Protein A-affinity chromatography
from filtered hybridoma supernatants. This purified material was
further subjected to anionic chromatography (Figure S1). The
mAb eluted as a single peak as evaluated both by TS-neutralizing
activity (not shown) as well as by TS recognition in dot-blot assays
(Figure S1). The same sequence was found in several mRNAs
encoding for the antibody (not shown), in support of a clonal
nature of the hybridoma. Purified mAb was proteolized with
papain to generate the Fab fragment. Inhibitory activity of the
fragment was determined and compared with that from the whole
IgG protein (Figure 1, panels B and C). Although the full-length
mAb appears to have a higher inhibitory activity (half maximal
inhibitory concentration IC50 5.6610
211 M), its Fab fragment still
retains a nanomolar IC50 (1.6610
29 M), clearly conserving its
antigen-binding mechanism. These high inhibitory potencies are
consistent with the apparent dissociation constant determined by
surface plasmon resonance (see above), even though IC50 figures
cannot be compared with affinity constants in absolute terms at
this point (allosteric effects, or yet mixed inhibition mechanisms,
may flaw a linear relationship). The purified Fab proved to be
fairly unstable when non-complexed to TS, requiring immediate
use for biochemical characterizations. This may be one of the
main reasons for the observed inhibitory potency decrease
compared to the entire immunoglobulin molecule. The Fab’s
instability precluded its use for further in vivo and in vitro biologic
assays.
Author Summary
Chagas’ disease, or American trypanosomiasis, is an
endemic illness that affects approximately 8 million people
in Latin America. The etiologic agent is the protozoan
parasite Trypanosoma cruzi. To survive in the mammalian
host and invade its cells, leading to the chronic infection,
the parasite incorporates a charged carbohydrate (sialic
acid). However, the parasite is unable to synthesize sialic
acid, having to scavenge it from the host’s sialo-
glycoconjugates, through a transglycosylation reaction
catalyzed by the enzyme trans-sialidase, which is unique
to these organisms. We have obtained a monoclonal
antibody that fully inhibits T. cruzi trans-sialidase actually
being, at the best of our knowledge, the most potent
inhibitor available. We now report a complete character-
ization of this neutralizing monoclonal antibody, at the
functional and molecular levels. The antibody displays very
high affinity and specificity for the T. cruzi enzyme, labels
the parasites’ surface and effectively blocks its sialylation
and host cell invasion capacities. The determination of the
3D structure of the enzyme-antibody immunocomplex by
X ray diffraction, allowed us to unveil the inhibition
mechanism, providing clues for rational drug design. Given
that sialidases are virulence factors in several pathogenic
microorganisms, the reported data shall help to expand
informative knowledge in this area.
Inhibition of TS by Neutralizing Antibodies
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which at least four families can be discriminated [31]. TSs are only
included in one of these families, which encodes for a number of
enzymaticallyactive and inactive members [32]. These twoforms of
TS can be distinguished by the single Tyr342His mutation [33]: only
the active TSs have the Tyr342 residue acting as the enzyme’s
nucleophile during the ping-pong reaction [34]. TS-mAb compe-
tition assays performed with the inactive TS showed that both
proteins reacted similarly with the mAb. An equimolar mixture of
inactive and active TSs, displayed ,50% reduction of the
neutralizing reactivity (Figure 1D). In a separate set of assays,
heat-inactivated TS was not recognized by the mAb 13G9 (Figure
S1), consistent with the hypothesis that the neutralizing epitope is
conformational [35]. In the infective trypomastigote stages, all TSs
include the SAPA C-terminal extension [31], which is absent in all
the other TS-related families allowing for clear-cut discrimination.
To address whether the mAb 13G9 was specific only for TS
proteins, extracts from biotinylated trypomastigotes were reacted
with the antibody (Figure 1E). Pulled-down material was subjected
to Western blot and developed in parallel with anti-SAPA (for TS)
and streptavidin for all the biotinylated parasite surface compo-
nents. Strong signals were readily observed in both lanes, matching
the TS expected protein sizes. No differential pattern was detected
whatsoever, confirming the very high specificity of 13G9 antibody
only towards proteins belonging to the TS family.
mAb 13G9 Reduces Cell Invasion and Inhibits the
Sialylation of the Parasite
The reactivity of mAb 13G9 with whole parasites was assayed
by immunofluorescence showing surface labeling consistent with
the expected cellular membrane localization of TS (Figure 2A).
The ability of the mAb to inhibit TS-mediated transfer of sialic
acid from the surrounding environment to the parasite’s surface
molecules was then tested. To reduce the basal sialylation of
parasites, sialyl residue donors were largely depleted replacing fetal
bovine serum (FBS) by bovine serum albumin (BSA) in the infected
tissue cultures; only host cells remained as the unique source of the
sugar. Trypomastigotes were then collected and incubated with
a(2,3)sialyllactose as sialic acid donor and TS, in the presence of
mAb 13G9. The amount of transferred sialic acid was determined
by the thiobarbituric acid method [36]. As shown in Figure 2B,
mAb 13G9 very efficiently inhibited the parasites’ sialylation,
demonstrating its biologic relevance as a TS-inhibitory molecule.
The sialylation observed in the treated parasites corresponds to the
sugar acquired before the addition of the mAb. These quantitative
results are in agreement with the Western blot assays we have
recently reported for sialyl-transfer inhibition by mAb 13G9 using
azido-modified sialic acids [37].
TS is involved in cell invasion [8,12] given that sialic acid is
required for competent interplay with the host cells. The ability of
mAb 13G9 to interfere with the invasion process was therefore
Figure 1. Biochemical characterization of the TS-13G9 mAb interaction. A) Surface plasmon resonance analysis of TS-mAb 13G9 interaction
kinetics. mAb 13G9 was immobilized onto a CM5 sensor chip and the indicated concentrations of TS were injected in the mobile phase. B, C) mAb
13G9 inhibition of TS activity. TS (2 ng) was mixed with increasing amounts of purified Fab (B), or whole 13G9 IgG (C) and remnant TS activity was
assayed. D) Competition assay for mAb 13G9-TS binding. TS activity was assayed (2 ng, 30 min) in the presence of the neutralizing mAb (3 and 6 mlo f
hybridoma culture supernatant diluted 1/20) and increasing amounts (from 0 to 8 ng) of the inactive TS (iTS) were added. Student’s t test was used.
* p,0.05; ** p,0.005 comparing against TS activity without mAb addition E) Specificity of the mAb 13G9. Trypomastigotes were biotinylated,
washed and mAb 13G9 added to pull-down reacting proteins. Western blots were developed with anti-SAPA (left) and streptavidin (right).
doi:10.1371/journal.ppat.1002474.g001
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number of infected cells, highlighting its biologic activity and
contributing direct evidence that TS is a valid target for drug
discovery.
3D Structure of the Immunocomplex Fab/TS
To gain atomic insight into the antigen-antibody interactions
allowing mAb 13G9 to neutralize the TS catalytic activity with
extremely high efficiency, we solved the structure of the
immunocomplex by X ray crystallography.
Crystallogenesis screenings were performed under a sitting-drop
vapor diffusion setup with a Honeybee963 robotic station, using
standard 96-well plates. Several initial hits were obtained. Further
manual optimization eventually allowed to grow crystals
(0.760.0560.05 mm) in polyethylene glycol (PEG) 20,000 plus
dioxane, suitable for X ray diffraction data to be collected (Table 1).
Limiting resolution was3.4A ˚ on a Cu rotating anode generator,and
indexing was straightforward, indicating a primitive cell in the
trigonal/hexagonal system. Cell parameters (a=b=178.1A ˚,
c=140.7A ˚) suggested the presence of as many as 3 binary
complexes per asymmetric unit, raising as well the hypothesis that
its weak diffraction could respond to limiting X ray beam intensity
inthecontextofafairlylargeunitcell(lownumberofscatteringcells
per crystal unit volume). To rule out this possibility, several crystals
were tested at the ALS (Advanced Light Source, Lawrence Berkeley
National Laboratory, Berkeley, CA) beamline 5.0.2 (8610
11 pho-
tons/s with 1.5 mrad divergence at 12.4 keV), with no detectable
improvement in resolution as judged by standard quantitative
statistics, strongly suggesting that crystal disorder linked to high
solvent content (66% as determined after full refinement) is the
major cause for maximum resolution sphere limitation.
No 6-fold peaks were found in self-rotation function maps, and
the k=180u section revealed significantly weaker signals than the
3-fold axis (data not shown) consistent with point group 3.
Systematic extinctions were observed in the reciprocal 00l axis,
strongly suggesting space groups P31 or P32. The structure was
solved by molecular replacement confirming SG P31. Two search
probes were used to calculate rotation and translation functions:
Protein Data Base (PDB) 3CLF (mouse IgG Fab fragment, chosen
according to sequence similarity to mAb 13G9) and 2AH2 (high
resolution T. cruzi TS model). Iterative cycles of maximum
likelihood refinement [38] were interspersed with manual
rebuilding [39]. The high resolution of the molecular replacement
search models resulted in excellent maps and straightforward
rebuilding, mostly adding missing side chains on the immuno-
globulin heavy and light chains. Tight non-crystallographic
symmetry restraints were kept only in the first refinement cycles,
thereafter allowing for automatic local NCS detection, with
variable weights according to evolving rms deviations, as
implemented in the program Buster/TNT [40]. Model refinement
statistics are summarized in Table 1. Interestingly, the PISA server
(European Bioinformatics Institute, Hinxton) predicts that the TS-
Fab 13G9 complex would not be stable in solution, contradicting
our experimental results. This discrepancy reveals the still
challenging task of predicting energetic and thermodynamic
properties of protein/protein associations, based on the analysis
of crystal structures of partners and derived complexes, despite the
fact that prediction algorithms are complex and attempt
integrating enthalpic and entropic effects, as well as solvent
accessible surface burial and geometric complementarity [41].
Indeed, three binary Fab-TS complexes are located in the
asymmetric unit, all very similar at the level of precision of our data.
Refined models of immunocomplex 2 (IC2, composed by TS chain
B, and chains I and M of the Fab molecule) and IC3 (TS chain C,
complexed to Fab J and N) were superposed sequentially onto
complex IC1 (TS chain A with H "heavy" and L "light" chains from
the Fab molecule) minimizing root mean squared deviations (rmsd)
of atomic coordinates. Such structural alignments resulted in 0.84A ˚
rmsd between IC1 and IC2, and 0.82A ˚ between IC1 and IC3.
Regions of highest variation correspond to intrinsically mobile
segments, as reflected by detailed analysis of atomic displacement
parameters (isotropic B factors). The mean B factor for all atoms is
relatively high (59.9 A ˚ 2), consistent with the low resolution to which
thesecrystalsdiffract Xrays.Crystal packingis indeedloose,leading
Figure 2. Reactivity of mAb 13G9 with T. cruzi parasites. A) T. cruzi surface labeling by the 13G9 mAb. Epifluorescence microscopy of T. cruzi
trypomastigotes, seeded onto poly-L-lysine-treated coverglasses, and immunolabeled with 13G9 mAb followed by a secondary FITC-labeled
antibody. B) Inhibition of parasite sialylation. Trypomastigotes obtained from cell cultures made in ‘low sialyl-donors’ conditions, were sialylated with
TS and sialyllactose, in the presence of mAb 13G9. Total sialic acid was quantified by the thiobarbituric acid method and referred to re-sialylated
parasites in the absence of mAb as 100% (approximately 1.2 pmoles of sialic acid/10
6 parasites). C) Effect of mAb 13G9 in infection assays on
mammalian cells. Parasites were preincubated for 1 h with 13G9 antibody (100 mg/ml) before infection. After 24 hrs, infected cultures were fixed and
stained with Hoescht 33342. At least 300 cells were counted.
doi:10.1371/journal.ppat.1002474.g002
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TS molecules display lower B factors then the Fab dimers to which
they are bound. A global tendency is also maintained among the
independent complexes, IC3 showing greater mobility than IC2,
which in turn is more flexible than complex IC1 (59.53.48 A ˚ 2),
probably due to the different packing environments. In the case of
the immunoglobulin heterodimers, chains also display a clear
difference among variable domains, more rigid, compared to the
constant domains,which showa reproducibleflexibilityonthedistal
half, away from the interdomain hinge.
Given the overall structural similarity among the three complexes
and the fact that complex IC1 resulted in a model with lower B
factors, subsequent analyses will be referred only to this complex.
Figure 3 shows the immunocomplex IC1 highlighting that the
variable regions of the Fab light chain are interacting with TS loops
located closerto the entrance of the enzyme’s catalytic pocket, while
the heavy chain associates to an adjacent, more distal patch.
The solvent accessible surface that becomes buried due to the
enzyme-antibody interaction corresponds to1810.2A ˚ 2 (916.5A ˚ 2 on
the TS and 893.7 A ˚ 2 on the Fab, adding 506 A ˚ 2 from the heavy
chain,and 387.7A ˚ 2 from thelight chain), withinthe typical range of
antibodies reacting with protein antigens. On this interface, 15
hydrogen bonds and one salt bridge can be distinguished, as well as
a number of residues that establish contact interactions (van der
Waals forces), as listed on Table 2. The resolution limit of the
diffraction data allowed for the identification of very few water
molecules, none of which are directly involved in the accessible nor
the buried surfaces engaged in interaction. The shape complemen-
tarity statistics [42] correspond to 0.673 and 0.645, after analysis of
the interface areas with the light and the heavy chains, respectively.
These figures are within the typical range (0.64–0.74) of specific
protein:proteininterfaces. The epitope (Figure 4) consists of residues
H171,Y 248,R 311–W312, and loops 199–201 (KKK) and 116–128
(SRSYWTSHGDARD - W120 and A126 do not interact directly).
The structural bases of the catalytic inhibitory effect that this
mAb elicits, can start to be elucidated by modeling the entrance of
the sialylated substrate into the TS reactional center in the context
of the TS-Fab complex (Figure 5). Superimposing TS PDB models
1S0I and 1S0J, onto our structure, allowed to define the positions
of the substrates N-acetyl-neuraminyl-lactose (a(2,3)sialyllactose)
and 4-methylumbelliferyl-N-acetyl-neuraminic acid (MU-NANA),
respectively (Figure 5). The most readily observable feature is the
steric hindrance that TS residue Y119 imposes, blocking the
entrance of the sialyl residue in the reactional pocket.
The free mobility of the phenolic side chain of Y119 is limited by
the juxtaposed residue S30 from the Fab’s light chain (Figure 5).
This restraint seems to play a central role in precluding the
entrance of sialylated substrates into the catalytic pocket, entrance
that absolutely requires the movement of Y119 [23]. A second
effect could not be excluded, namely the spatial constraint exerted
by the overall architecture of the associated complex. Residues
S26–S28 (within the light chain complementarily determining
Table 1. Data processing and refinement statistics.
TS-mAb 13G9 complex
Space group P3 1
Wavelength (A ˚) 1.5418
Data Resolution (A ˚)
a 40–3.4 (3.58–3.4)
Measured reflect. 68611
Multiplicity
a 3.6 (3.5)
Completeness (%)
a 99.8 (100)
Rmeas (%)
a,b 19 (51.6)
,I/s(I).
a 6.7 (1.5)
abc( A ˚) 178.1 178.1 140.7
Refinement resolution (A ˚) 29.8–3.4
Rcryst
c [Nu refs] 0.165 [67573]
Rfree
c [Nu refs] 0.205 [1014]
Rms bonds (A ˚) 0.013
Rms angles (u) 1.53
Protein non-hydrogen atoms 24414
Water atoms 42
Ligand atoms 13 (2 dioxanes + 1N a )
Residues in Ramachandran plot regions
d(preferred + allowed/outliers) 3109/35
PDB ID 3OPZ
aValues in parentheses apply to the high-resolution shell.
bRmeas~
X
h
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ﬃ
Nh=(Nh{1)
p X
i
Ii{SI+T jj
,
X
h
X
i
I+;N h, multiplicity for each reflection; Ii, the intensity of the i
th observation of reflection h; ,I., the mean of the
intensity of all observations of reflection h, with I+~1=Nh
X
i
I({)orI(z) ðÞ ;
X
h
is taken over all reflections;
X
i
is taken over all observations of each reflection.
c; R~
X
h
F(h)obs{F(h)calc jj
,
X
h
F(h)obs jj ;R cryst and Rfree were calculated using the working and test hkl reflection sets, respectively.
dTotal refined protein residues equal 3172, from which 28 terminal amino acids (the N- and C-termini on the 9 chains; plus residues: TS#399, TS#409 (in chains A, B & C),
Fab#27, Fab#29 (in chain H), Fab#137, Fab#139 (in chain I), all flanking unmodeled gaps) were not included in the Ramachandran analysis (as implemented in Coot v
0.6.2-pre-1).
doi:10.1371/journal.ppat.1002474.t001
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direct contact with TS residues R311 and W312. This interaction is
located just on top of the catalytic pocket entrance, functioning as
a ‘roof’ (SG/RW roof), where the catalytic center itself would be
the floor. As shown in Figure 5B, when sialyllactose is located in
position, the substrate pocket appears to be too small, predicting
direct clashes of the glucosyl residue with the SG/RW roof
(particularly residues Ser66–Gly67 of the Fab light chain). This
scenario of course implies that Y119 could eventually be forced to
move out of the sialic acid binding site, an unlikely event. The light
chain loop 29–31 is also prone to interfere with the saccharide, if
rearrangements are to be considered during its accommodation
(data not shown). In order to obtain further experimental data
evaluating the relative effects of Y119-mobility hindrance and/or
the spatial constraints exerted by the SG/RW roof onto the
catalytic pocket cavity volume, MU-NANA was assayed in TS-
catalyzed sialidase reactions. MU-NANA is an artificial substrate
that allows for TS-catalyzed hydrolytic and trans-glycosidase
activities [43], and given its smaller volume, could better
accommodate, avoiding steric clashes with the SG/RW roof
structure (Figure 5B). TS-mediated MU-NANA hydrolysis was
efficiently inhibited by mAb 13G9 (Figure 6), suggesting that the
immobilization of Y119 does play a central role. The spatial
confinement in the pocket, partly due to the SG/RW roof
structure, might impose secondary constraints precluding torsional
accommodation, even in the case of smaller compounds.
Discussion
This report describes an extensive biochemical and structural
characterization of the mouse mAb 13G9, which is herein
demonstrated to act as a powerful inhibitor of the T. cruzi TS
catalytic activity, displaying high specificity and affinity for the
enzyme. T. cruzi TS is a virulence factor required for the survival
of the parasite in the mammalian host. Several different biologic
activities of the enzyme can be discriminated. The parasite uses TS
Figure 3. Overall structure of one binary immunocomplex. Immunocomplex 1 (IC1 as defined in the text) is depicted as a background cartoon
representation with a superposed transparent solvent-accessible surface rendered in colors. trans-Sialidase is colored green, Fab light chain magenta
and heavy chain cyan. The antibody light chain is slightly occluding the entrance of the enzyme’s catalytic pocket, while the heavy chain is more
eccentric, establishing a large interaction surface on one side of the reaction center.
doi:10.1371/journal.ppat.1002474.g003
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lysis by serum factors [9,10]. In this context, it should be noted
that the addition of mAb 13G9 inhibited this sialylation process
(Figure 1) in agreement with our previous findings with azido-
modified sugars [37]. As well, TS is not only directly involved in
the parasite/host cell interaction through the generation of a
Table 2. Residues that display a significant change in solvent-accessible surface, comparing the separate and complexed
structures of TS and mAb 13G9.
Heavy chain Light chain TS (interface with heavy chain) TS (interface with light chain)
Tyr 31* Ser 28 Ser 115 1 Asn 60 1
Asp 32{ Ser 30 Ser 116 Val 91 1
Trp 33* His 31 Arg 117* Arg 117*
Tyr 52* Tyr 48* Ser 118* Ser 118
Tyr 57 Ile 49 Ser 122* Tyr 119
Ile 58 Tyr 52 His 123 Thr 121
Asn 59* Ser 66* Gly 124* Ser 122
Tyr 60 Gly 67 Asp 125* Lys 200
Arg 98 1 Trp 90* Arg 127{ Lys 201*
His 100 1 Ser 91 Asp 128 Gln 202
Tyr 101* Thr 92 His 171 Tyr 248
Asp 102* Phe 93 Lys 199* Arg 311*
Gly 103* Lys 200* Trp 312
Ser 104* Lys 201
Tyr 105 1
*also establishes hydrogen bonds.
{also establishes salt bridge.
1no direct contact is observed.
doi:10.1371/journal.ppat.1002474.t002
Figure 4. Close-up of the TS/antibody interface. Highlight of the spatial distribution of the epitope residues (in stick representation, colored
yellow). TS is shown in orange, light Fab chain in magenta and heavy chain in cyan. For clarity not all the epitope residues are shown nor labeled (see
text for full analysis). On top of the cartoon secondary structure representation, residues are represented in lines for the three chains. As a reference
for TS positions within the reaction center, the catalytic amino acids Y342 (on the floor of the pocket) and D59 are highlighted as green sticks; Y119
(colored red) forms part of the epitope, normally flexible in free TS. Note how the mAb light chain precludes free mobility of Y119, which plays a key
function in trans-glycosylation.
doi:10.1371/journal.ppat.1002474.g004
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parasitophorous vacuole to the cytoplasm [12]. In concert with
these findings, here we report that mAb 13G9 significantly reduces
parasite infection of cell cultures (Figure 1). Passive transfer of
neutralizing mAb 13G9 to heavily infected mice, protects them
against TS-induced deleterious effects on the immune system and
platelets [5,17]. In this sense, it is well known that antibodies
against neuraminidases are also effective in preventing other
diseases such as Influenza [44]. These protective effects are very
much promising to delineate a therapeutic tool. The high
molecular weight of antibodies constitutes a main drawback in
their use, due to eventual hindrance for effective diffusion into
infected tissues, where high concentrations of locally produced TS
are expected to be found. On the other hand, Fab fragments, small
recombinant antibody-derived molecules (e.g. scFv), or yet
antibody-mimetic engineered molecules [45], can be cleared
exceedingly fast from the bloodstream [46], resulting in poor
pharmacokinetic figures. PEGylation, and other modifications to
improve bioavailability of these smaller protein scaffolds, consti-
tute interesting approaches to be tested using mAb 13G9 as
starting lead [47].
As a second interesting avenue to explore for therapeutic
derivatives, the high affinity and specificity of this mAb, prompted
us to elucidate its neutralizing mechanism, as an attempt to
thereafter conceive low molecular weight inhibitors, suitable as
chemotherapy leads. Some information can be gathered in this
respect from previous studies of the neuraminidase from Influenza
virus, a protein orthologous to TS. The overall geometry of the
antibody/TS association that we are now reporting, is reminiscent
of the one described for a Fab/Influenza-N2 neuraminidase
complex (PDB 2AEP; [48]), which shows interaction with
enzyme’s loops on the same side of the reaction pocket, opposite
to the patch where most other anti-neuraminidase antibodies have
been reported (such as the ones involving avian N9 neuraminidase
with antibodies NC41 and NC10, PDBs 1NCA and 1NMB,
respectively; among others) [49–51]. The interaction surfaces of
TS-13G9 mAb (this report) and N2NA-Mem5Fab (2AEP) are
Figure 5. Sialoconjugate substrates modeled in the TS reaction center, in the context of the immunocomplex structure. (A)
a(2,3)sialyllactose (SL, carbons in yellow) and MU-NANA (carbons in purple) are shown in stick representation, colored according to atom elements
(oxygen in red, nitrogen in blue). The carbohydrates are grafted from PDB models 1S0I (for SL) and 1S0J (MU-NANA), after structural superposition of
the TS molecules onto the immunocomplex, resulting in their specific positions within the TS catalytic pocket. TS and Fab molecules are shown in
ribbons (TS in green, Fab light chain in magenta and heavy chain in blue), with their corresponding solvent-accessible surfaces on top. The surface
has been cut to highlight the inner architecture of the TS catalytic pocket: this orientation does not allow appreciating that the site is open from
above and beneath the plane of the paper. TS Y119 (green sticks) is seen directly obstructing the sialic acid position, and its normal mobility is
hindered by antibody’s light chain S30 (magenta sticks). (B) A similar representation as in panel (A), in a rotated orientation scene, to highlight the
‘roof’ formed by residues S66–G67 of the Fab light chain (in magenta sticks to the top left of the panel) in direct contact with TS residues R311–W312 (in
pale green sticks, to the right of the figure). Note the expected clash of the glucosyl residue in sialyllactose against loop 66–67, and the better fit of
the smaller MU-NANA substrate, still quite restricted in free torsional movements. Y119 is again shown (strong green sticks), precluding entrance of
the sialic acid moiety of both modeled sugar compounds.
doi:10.1371/journal.ppat.1002474.g005
Figure 6. mAb 13G9 inhibits TS-catalyzed MU-NANA hydroly-
sis. TS (50 ng) was incubated with increasing amounts of 13G9
hybridoma supernatant for 10 min as indicated, then 200 mM MU-NANA
was added and incubation continued for 30 min. Controls with
complete medium were run in parallel.
doi:10.1371/journal.ppat.1002474.g006
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configurations with respect to the location of the heavy and light
chains. Well defined escape mutations in Influenza (loops
including positions 198–199 and 220–221, following N2 Influenza
numbering scheme) identify epidemiologically important antigenic
sites of neuraminidase, revealing antigenic drift in human viruses
seemingly under natural antibody selection of enzyme variants
[52]. These loops, connecting b2–b3 within the second blade of
the six-bladed b-propeller domain, and b4 of this blade with b1o f
the next one, are not structurally conserved between T. cruzi and
Influenza enzymes, being longer in the former. Nevertheless, it is
clear that the equivalent loops in T. cruzi TS do play a critical role
in the 13G9 Fab association that we are now reporting.
One of the specific mAb loops that interact in a proximal
position to the catalytic pocket of the enzyme, was observed
precluding the displacement of Y119, a critical residue that has
already been shown to be flexible in TS [24,53]. Indeed, the
mobility of Y119 plays a key role in the trans-glycosidase mechanism
of TS. The determination of the three-dimensional coordinates of
the paratope, including these features that lead to spatial
constraints, uncovers relevant information. This is to be used as
a precise guide, not only to undertake peptidomimetic syntheses,
but most importantly, to use as a working template for the
synthesis of non-peptidic molecules including critical pharmaco-
phores [54].
Materials and Methods
Ethics Statement
The protocol of this study was approved by the Committee on
the Ethics of Animal Experiments of the Universidad Nacional de
San Martı ´n, which also approved protocol development under the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
Recombinant Enzymes
Recombinant T. cruzi TSs (constructs 1N1, 2Vo, D1443TS and
3.2) [24,28,33], T. rangeli sialidase [23] and T. brucei TS [55] were
used. The 1N1 and 2Vo clones correspond to the full-length
(including the SAPA repeats [33]) wild type genes that encode for
enzymatically active and inactive molecules, respectively. The
D1443TS recombinant TS was used for immunization procedures.
D1443TS is an engineered variant where the deletion of a non-
neutralizing epitope in the globular domain was done [28]. The
TS 3.2 construct [24] is engineered to express the enzymatically
competent globular domain only, containing seven mutations of
surface-located residues that allow for protein crystallization. All
TSs were expressed in Escherichia coli BL21 and immediately used
after purification, avoiding .3 weeks storage at 4uC. Recombi-
nant proteins were purified to homogeneity as described elsewhere
[56], briefly, TS was subjected to immobilized metal affinity
chromatography (Ni
++-charged, Hi-Trap Chelating HP) followed
by MonoQ anionic exchange chromatography (both from GE-
Healthcare).
Mice, Immunization Procedures and Neutralizing Titer
Determination
C3H/HeJ male animals (60 day old) were used. Mice received
three intramuscular doses of D1443TS recombinant enzyme [28],
10 mg each with 100 mg of thiophosphodiester backbone CpG-
ODN 1826 oligonucleotide (59-TCCATGACGTTCCTGACG-
TT-39, CpG motifs underlined) (Sigma-Genosys) as adjuvant [57].
TS-inhibition assay was performed as previously described [30],
preincubating sera with TS and then testing for remnant activity
using a(2,3)sialyllactose (Sigma) and [D-glucose-1-
14C]-lactose (GE-
Healthcare) as donor and acceptor substrates, respectively. Best
responders were selected for cell fusion procedures.
Hybridoma Screening and mAb Production
Splenocyte suspensions were mixed with Sp2/0-Ag14 cells
(ATCC) and fusions performed with polyethylene glycol (GIBCO)
following standard procedures [58]. Cells were seeded on 96-well
flat-bottom plates at a density of 1610
5 cells/well in RPMI 1640
with 2 mM Na Piruvate, 10% FBS, 1X hypoxanthine-aminop-
terin-thymidine (HAT) solution (all from Invitrogen) and supple-
mented with 2% supernatant of Sp2/0–Ag14 cultures. One-week
later, plates were observed under microscopy and the supernatant
of those wells containing hybridomas were taken and refilled with
fresh medium. ELISA was performed with these samples in search
for TS-specific antibody production. To preserve discontinuos
epitopes, the recombinant TS 1N1 containing the C-terminus
repetitive extension (SAPA) was linked to the plate (MaxiSorb,
NUNC) by Protein A-Sepharose (HiTrap, GE-Healthcare)-
purified rabbit IgG anti-SAPA, a procedure that safely retained
the enzymatic activity (not shown). Those culture wells where anti-
TS antibodies were detected were further assayed by TS-inhibition
assay [30]. Hybridomas secreting neutralizing antibodies were
cloned twice by cell dilution. From four inhibitory antibody-
secreting hybridomas detected, only one (named 13G9) was
successfully recloned twice by the dilution method and then
expanded. The mAb 13G9 was typed as IgG2ak using the Mouse
Antibody Isotyping Kit (GIBCO).
mAb Production and Purification
The 13G9 hybridoma was cultured in RPMI 1640 plus 2 mM
Na Piruvate and 10% FBS. Supernatants were clarified and
subjected to Protein A-Sepharose (GE-Healthcare) affinity chro-
matography. The mAb was eluted with 150 mM NaCl, 0.1 M
Glycine-HCl pH 3.5 and aliquots were received on 0.1 M Tris-
ClH pH 7.6 and dialyzed against 50 mM NaCl, 20 mM Tris-
HCl, pH 7.6. Fractions were then loaded into an ion-exchange
column (MonoQ, GE-Healthcare) and eluted with a 50–500 mM
NaCl gradient in the same buffer (Figure S1). Purified 13G9 mAb
was tested by TS-inhibition assay [30] and by reactivity to native
and denatured TS-SAPA molecules spotted on nitrocellulose
(Figure S1).
Sequence Analysis
cDNA was obtained from 13G9 hybridoma cultures from total
RNA using the SuperScript II retrotranscriptase (Invitrogen).
cDNA quality control was performed by GAPDH amplification.
To amplify the immunoglobulin Fab chains, oligonucleotide
primer sets Fwh1 (59-GTCAGGAGTTGAGCTGGTAAG-39),
Fwh2 (59-CCTGGGACTTCAGTGAAGATG-39) and Rvh (59-
TGGAGGACAGGGCTTGATTG-39) were used for the heavy
chain, and Fwl1 (59-AACAATCATGTGTGCATCTATA-39),
Fwl2 (59-GAGGAGATCACCCTAACCTG-39) and Rvl (59-TC-
AGGATGTGGTTGCAACAC-39), for the light chain. Pfu DNA
polymerase (Promega) was used and amplicons cloned and
sequenced.
Determination of Kinetic Parameters of mAb 13G19
Reactivity
The association/dissociation kinetic constants (kon/koff) were
determined with a BIAcore 2000 (BIAcore AB, Uppsala, Sweden).
Purified mAb was dialyzed against 20 mM sodium acetate pH 5.6
and immobilized to sensor chips CM5 by using the amine-
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ethanolamine/HCl. After equilibration with 150 mM NaCl,
0.05% P20 surfactant, 10 mM HEPES pH 7.4 (HBS-EP),
different concentrations of TS (from 1 nM to 10 mM) were
injected at 50 ml/min. After each recording cycle, chips were
regenerated with an injection of 2 mM HCl for 30 sec. A free
surface of the chip was used as control throughout the
experiments. Kinetic constants were evaluated using the program
BIAevaluation 3.01 (BIAcore AB). Isothermal titration calorimetry
assays were performed in the laboratory of Dr. Alan Cooper
(Department of Chemistry, Joseph Black Building University of
Glasgow, UK).
Inhibition constants of TS activity were determined for mAb
13G9 and its derived Fab fragment (see below for digestion details)
by testing increasing amounts of inhibiting antibody with 2 ng of
TS in 30 ml of 150 mM NaCl, Tris-HCl pH 7.6. After 5 min at
room temperature (RT), 1 mM sialyllactose and 0.4 nmol (about
40,000 cpm) of [D-glucose-1-
14C]-lactose (54.3 mCi/mmol, GE-
Healthcare) were added. Remnant TS activity was evaluated [30]
after 30 min incubation at RT.
Specificity of mAb 13G9 Reactivity
Trypomastigotes (120610
6) were purified from supernatants of
infected Vero cell cultures, biotinylated (Sulfo-NHS-LC-Biotin kit
form Pierce, Rockford, IL) washed and lysed in the presence of
protease inhibitors and centrifuged at 16,000 g. Supernatant was
precleared with Protein A-Sepharose (GE-Healthcare) and then
reacted with 50 ml of mAb 13G9 hybridoma supernatant for
30 min. Then, Protein A-Sepharose was added and beads
extensively washed before SDS-PAGE sample buffer addition
and boiling. SDS-PAGE was performed with two parallel aliquots
that were then transferred to polyvinylidene fluoride (PVDF)
membrane (GE-Healthcare) and developed with either rabbit IgG
anti-SAPA followed by horseradish peroxidase (HRP)-labeled
secondary antibody or HRP-streptavidin and Super Signal West
Pico Chemiluminescent substrate (Pierce).
Inhibition of Parasite Cell Invasion
T. cruzi trypomastigotes (CL-Brenner strain) obtained from
Vero cell cultures (Minimum Essential Medium (Invitrogen)
supplemented with 0.2% BSA instead of FBS to reduce sialic
acid donors) were exhaustively washed with PBS. Parasites were
tested by infection of Vero and HeLa cell cultures in the same
medium at a multiplicity of infection of 30 in the presence of
0.1 mg/ml of mAb 13G9. After 3 h, cells were washed and
medium plus 10% FBS was added. Cells were fixed and stained
24 h later for counting infected cells under microscopy. IgG
purified from naı ¨ve mouse was used as control.
Inhibition of Parasite Sialylation
Parasites obtained under low sialic acid conditions as above
were incubated with 1 mM sialyllactose (Sigma) as sialyl residue
donor substrate and TS (2 mg/ml) with or without mAb 13G9
(0.1 mg/ml). After washings with PBS, sialyl residue content was
determined by the thiobarbituric HPLC assay after hydrolysis in
0.1 M HCl for 1 h at 80uC [36]. IgG purified from naı ¨ve mouse
was used as control.
Immunofluorescence
Cell culture-derived trypomastigotes were washed with PBS and
incubated with mAb 13G9 (0.05 mg/ml) for 15 min, washed,
fixed with 1% paraformaldehyde for 10 min on ice, washed again
and blocked for 1 h with 2% BSA plus 5% swine serum in PBS.
After that, the parasites were adhered to glass slides via Poly-L-
Lysine (Sigma), blocked again, developed with a FITC-conjugated
secondary antibody (DAKO, Denmark) and observed by epi-
fluorescence microscopy.
Inhibition of Sialidase Activity
The sialidase activity of TS was determined by measuring the
fluorescence of 4-methylumbelliferone released by the hydrolysis
of 0.2 mM MU-NANA (Sigma). To 50 ng of TS, different
amounts of hybridoma culture supernatant (0–10 ml) or RPMI
plus 10% FBS (control) were added. The assay was performed in
50 ml of 150 mM NaCl, 20 mM Tris-ClH pH 6.8. After 10 min at
RT, 200 mM of MU-NANA was added and incubation continued
for 30 min. The reaction was stopped by dilution in 0.2 M
NaHCO3 pH 10, and fluorescence was measured with a DYNA
Quant TM 200 fluorometer (GE-Healthcare). Fluorescence values
were referred to each RPMI control.
Generation of Antibody Fragments and Immunocomplex
Purified mAb was dialyzed against 2 mM EDTA, 0.1 M Tris-
HCl pH 7.6. Before papain digestion 1 mM dithiothreitol (DTT)
was added. Papain-agarose beads (Sigma) were washed with the
same buffer and activated by addition of 1 mM DTT for 15 min
at 37uC. The Fab fragment was generated by digestion for 5 h at
37uC with papain-agarose beads (3U papain/mg mAb; 30 mg of
beads for 14 mg of mAb) with gentle end-over-end agitation [58].
After centrifugation at 3,000 rpm, 10 mM trans-epoxysuccinyl-L-
leucylamido(4-guanidino)butane (E-64) was added. Undigested
antibody and Fc fragment were depleted by Protein A-Sepharose
(GE-Healthcare) chromatography and Fab digestion and purity
was assayed by SDS-PAGE.
To generate the immunocomplex, pure TS (3.2 clone) was
immediately added after the depletion of papain-beads and E-64
addition step before subjecting the mixture to Protein A-Sepharose
chromatography as above (Figure S1). The immunocomplex was
brought to 25 mM NaCl and concentrated on a BIOMAX 30 K
(Millipore) to 14 mg/ml and the buffer changed to 25 mM NaCl,
20 mM Tris-HCl pH 7.6. The purified immunocomplex was
essentially free from contaminating proteins and only traces of TS
activity remained (see Figure S1). Before crystallization trials, the
immunocomplex was repurified by size exclusion chromatography
(Superdex200 10/300, GE Healthcare) in an AKTA Purifier, (GE
Healthcare) with isocractic elution in 100 mM NaCl, 20 mM Tris-
HCl pH 7.6. The resulting single symmetric peak was pooled and
concentrated to 7.5 mg/ml by ultrafiltration (Vivaspin, Sartorius-
Stedim Biotech; 30 kDa-cutoff membrane) in buffer 25 mM NaCl,
20 mM Tris-HCl pH 7.6.
Immunocomplex Crystallization
Crystallogenesis conditions were screened with a HoneyBee 963
robot (Digilab), using the vapor diffusion method in sitting-drops
and reservoirs filled with 150 ml mother liquors (kits JCSG Core
Suites I, II, III and IV, Qiagen), rendering 396 different conditions
in 96-well plates (3-drop round bottom, Greiner). Protein drops
were dispensed mixing equal parts of protein and reservoir
solutions (300 nl + 300 nl). Plates were immediately sealed and
incubated at 20uC. Hits were obtained in several conditions, one
of them was chosen for manual optimization in 24-well plates
(VDX, Hampton Research). Final optimized conditions consisted
in 2+2 ml hanging-drops, 0.1 M bicine pH 8.5, 10% PEG 20,000,
4% 1,4-dioxane as mother liquor. To obtain larger crystals
suitable for single crystal X ray diffraction experiments, repeated
macroseeding cycles proved to be essential. Each cycle included
selection of best crystal seeds that were transferred to protein-free
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procedure was repeated three times). Finally, the seed was added
to a fresh hanging-drop containing 2 ml protein + 2 ml mother
liquor, over 1 ml pure mother liquor. Single needles grew in 5–10
days, cryoprotected with mother liquor containing 12% PEG
20,000 and 30% glycerol and flash frozen in liquid nitrogen until
data collection.
Crystal Structure Determination
Single crystal X ray diffraction experiments were performed
with a rotating copper anode (Micromax007-HF, Rigaku),
multilayer mirrors (Varimax HF, Rigaku) and an image plate
detector (Mar345 dtb, Mar Research). Crystals were mounted to
collect data under cryogenic temperature (108uK, Cryostream
Series 700, Oxford Cryosystems). To attempt improving diffrac-
tion resolution, similar crystals were subjected to X ray diffraction
using synchrotron radiation at beamline 5.0.2 ALS, equipped with
a wiggler inserted device. All data sets were processed with
MOSFLM [59], SCALA and TRUNCATE [60].
The structure was solved by molecular replacement with the
program Phaser [61], using the models 3CLF (mouse IgG Fab)
and 2AH2 (T. cruzi TS in complex with 3-flourosialic acid) as
search probes. The Fab probe was previously modified using
Chainsaw [60], keeping only the conserved side chains, the rest
pruned to alanine or glycine.
The model was refined to the highest collected resolution (3.4 A ˚)
with the program Buster/TNT [38], using a maximum likelihood
target function and non-crystallographic restraints throughout the
entire process. A TLS model was used to refine correlated
anisotropic atomic displacement parameters in large rigid-body
domains. Reciprocal space refinement cycles were iterated with
manual model rebuilding [39]. Validation tools within Coot were
inspected regularly during the refinement process. Last validation
steps were done with MolProbity [62].
Accession Numbers
The atomic coordinates and structure factors of the Fab-TS
immunocomplex that we have solved in this report are accessible
in the PDB with accession code 3OPZ. The models used to solve
the phase problem have PDB accession codes 3CLF (mouse IgG
Fab fragment) and 2AH2 (T. cruzi TS). A certain number of
sialidase and trans-sialidase structures solved previously by us or by
other groups, are mentioned in the Discussion section and can be
accessed in the PDB with codes: 2AEP (Fab/Influenza-N2
neuraminidase complex); 1NCA (avian N9 neuraminidase com-
plexed with antibody NC41); 1NMB (avian N9 neuraminidase
complexed with antibody NC10); 2AEP (N2NA-Mem5Fab); 1S0I
(T. cruzi TS in complex with sialyllactose) and 1S0J (T. cruzi TS in
complex with MUNANA). Sequence of T. cruzi trans-sialidase can
be accessed from the GenBank with the code L26499.
Supporting Information
Figure S1 Production of the mAb 13G9-TS immuno-
complex. A) MonoQ-chromatogram of Protein A-purified
hybridoma 13G9 supernatant. The mAb eluted as a single peak.
B) TS reactivity of eluted and pass-trough proteins. Nitrocellulose
membranes were spotted with TS-SAPA native (1) or heat-
denatured (2). Upper panel was tested with flow through proteins,
middle panel with the eluted peak and lower panel with an anti-
SAPA mAb. Filters were developed with an HRP-labeled
secondary antibody against mouse immunoglobulins. Note the
absence of reactivity to the denatured protein by the 13G9 mAb
(middle panel, spot 2) in contrast with the anti-SAPA mAb that
recognizes a continuous epitope (lower panel). C) Purification of
the Fab-TS complex through a Protein A affinity column. The
retained protein corresponds to the Fc fraction. D) SDS-PAGE of
the purified TS-Fab complex. E) Almost null remnant TS activity
was found in the TS-Fab complex.
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